Apr 22 |
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
|
Apr 10 |
Kura Oncology to Participate in Stifel Targeted Oncology Forum
|
Mar 10 |
Cantor sees strong year ahead for oncology M&A
|
Mar 6 |
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
|
Feb 28 |
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript
|
Feb 28 |
Q4 2023 Kura Oncology Inc Earnings Call
|
Feb 28 |
Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript
|
Feb 28 |
Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation
|
Feb 27 |
Kura Oncology Inc (KURA) Reports Q4 and Full Year 2023 Financial Results
|
Feb 27 |
Kura Oncology GAAP EPS of -$0.55 in-line
|